2024 Award Winners

The projects or startups that have been awarded the Attractive Innovation Project award by UU Innovation are regularly presented here.

Lea Cares

Lea Cares is commercialising an innovative technology that enables the release of the minerals silicon and calcium locally, resulting in increased collagen growth that can contribute to stronger hair, skin and nails. The company's first product is a nail oil, which was launched in 2023. More cosmetic products are in development and the company also sees opportunities for more application areas. Earlier this year, Lea Cares received a patent for its bioactive mineral technology in Europe and has received seed investment through Linnéa Capital and attracted angel capital.

The inventors of the technology, and founders of Lea Cares, are Viktoria Engqvist, Master of Science in Pharmacy, and Håkan Engqvist, Professor of Applied Materials Science at Uppsala University.

Lea Cares online

Håkan Engqvist och Viktoria Engqvist med blommor och diplom

Håkan Engqvist and Viktoria Engqvist are the founders of Lea Cares AB.

Phenaros Pharmaceuticals

Jordi Carreras Puigvert and Ola Spjuth, from the Department of Pharmaceutical Biosciences, have devised a screening method for potential drugs. By integrating artificial intelligence with phenomics, which involves large-scale morphological profiling, and automation, this approach can furnish crucial insights into the promise of new drug candidates from an early stage. Consequently, it holds the promise of accelerating the identification and advancement of genuinely promising drug candidates for pharmaceutical companies, thereby saving valuable time and resources.

The research team has established Phenaros Pharmaceuticals AB, which secured its initial investment through Connect Uppsala's network and also achieved its first sale. With the objective of expediting and ensuring the safety of drug development, the team is actively exploring the most viable routes to market.

Phenaros Pharmaceuticals online

Ola Spjuth och Jordi
Carreras Puigvert med diplom och blommor

Ola Spjuth and Jordi Carreras Puigvert have established Phenaros Pharmaceuticals AB to commercialise their promising screening method for potential drugs.

SeisMove

The demand for precise ground surveys in urban environments has risen due to significant investments in advanced infrastructure projects such as tunneling. Concurrently, seismic surveys in cities, tunnels, and mines face particular challenges related to electrical noise and logistical constraints. To enhance measurements in these challenging settings, Professor Alireza Malehmir and his team from the Department of Earth Sciences have developed a seismic landstreamer. This innovative solution features numerous sensors mounted on sleds that can be connected and towed, for instance, behind a vehicle, often a seismic source.

The landstreamer has been tested in various infrastructure projects, including tunneling, CO2 storage, and mining environments. The results indicate significant potential, attracting substantial global interest and leading to commercial sales. The landstreamer incorporates patented technology and is registered under the SeisMove trademark.

Grzegorz Paletko, Alireza Malehmir och Magdalena Markovic med diplom och blommor.

Alireza Malehmir (center) with colleagues Grzegorz Paletko and Magdalena Markovic, who have been involved in the development and first commercial sale of SeisMove.

AVulotion

Acute myocardial infarction (AMI) with subsequent heart failure is the leading cause of hospitalisation and death in the Western world. In Sweden, nearly 18 000 people per year suffer from AMI, including almost 6 000 from STEMI – a condition typically involving a complete blockage of a coronary artery. A major issue with the current standard treatment for STEMI patients is that it can cause additional damage to heart tissue, increasing the risk of complications such as heart failure.

In close cooperation between research and clinical practice, Karl-Henrik Grinnemo, Sergey Rodin, and Oscar Simonson at the Department of Surgical Sciences have developed a concept to generate extracellular vesicles (CARMEV) that are immunomodulatory and have proven effective in preventing heart failure after myocardial infarction and in other severe inflammatory conditions. This makes CARMEV the first biological product capable of preventing damage caused by the treatment of acute myocardial infarction. Supported by an investment from UU Invest AB, the research team has founded the company AVulotion to scale up the production of CARMEV, in collaboration with NorthX Biologics. Their goal is to create a standard medication for the treatment of patients with myocardial infarction.

Porträttbild av Sergey Rodin, Karl-Henrik
Grinnemo och Oscar Simonson med blommor och diplom.

In close cooperation between research and clinical practice, Sergey Rodin, Karl-Henrik Grinnemo, and Oscar Simonson at the Department of Surgical Sciences have developed CARMEV and founded the company AVulotion to pursue their goal of creating a standard medication for the treatment of patients with myocardial infarction.

HuMIX TEER

A research team from the Department of Materials Science at Uppsala University, consisting of Professor Maria Tenje, researchers Laurent Barbe and Sofia Johansson, and PhD student Gabriel Werr, has developed HuMIX TEER in collaboration with colleagues from the University of Luxembourg. This innovative technology enables detailed studies of gut microbial interactions, offering valuable insights for the development of new drugs and nutritional supplements.

HuMIX TEER is based on a microfluidics model with integrated flexible electrodes, allowing real-time measurement of gut barrier integrity. The model mimics the interactions between human cells and microorganisms in the gut. The technology is patent pending, and the Uppsala team has transferred its share of the patent application to the University of Luxembourg, which is now exploring commercialisation opportunities.

Forskarteamet bakom HuMIX TEER vid institutionen för materialvetenskap

Meet the team behind HuMIX TEER, pioneering real-time studies of gut microbial interactions for future drug and supplement development – Gabriel Werr, Maria Tenje, Laurent Barbe and Sofia Johansson.

FOLLOW UPPSALA UNIVERSITY ON

facebook
instagram
twitter
youtube
linkedin